SOUTH SAN FRANCISCO, Calif.– Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the promotion of Patrick Finn, Ph.D. to the newly created position of president and chief operating officer. Dr. Finn previously served as chief commercial officer of Twist Bioscience.
“Paddy joined Twist eight years ago, establishing our sales and marketing team and growing sales from $2 million in fiscal 2016 to sales of $184 million for the 12 months ended June 30, 2022. Over his tenure at Twist, he has excelled and taken greater spans of control, with increasing responsibility, resulting in this promotion,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “As we expand our footprint globally, Paddy brings a customer-centric focus to every aspect of our operations, augmenting our senior leadership team across all areas of the business, and I look forward to his forward-thinking, strategic leadership as we continue to increase our market share across synthetic biology, NGS and biopharma, as well as launch a commercial product for data storage.”
Dr. Finn will continue to oversee the commercial team, headed by strong sales leaders in the Americas, Europe and APAC, and will now extend his scope to include operations.
“During my time at Twist, I have had the privilege of working closely with our customers and with the Twist teams that interact with them directly. I look forward to the expanded responsibility of overseeing operations to drive exceptional product quality, superior customer experience, faster turnaround times and fiscal responsibility to bring our solutions to established and new customers globally,” said Dr. Finn.
Dr. Finn joined Twist in 2015 to build the company’s sales force in advance of the launch of its commercial synthetic DNA products. In 2019 he was promoted to chief commercial officer, responsible for global commercialization of all products in addition to commercial development activities. He joined Twist from Enzymatics (now QIAGEN), where he was vice president of sales, leading commercial activities for North America and Europe. Prior to Enzymatics, he held positions of increasing responsibility, including director of business development at Agilent Technologies, director of product development for Beckman Coulter, and multiple technical roles in product development within Invitrogen and GE Healthcare/Amersham International. Dr. Finn serves on the Board of Directors at ONI and previously served on the scientific advisory boards of Lasergen and Enzymatics. He holds a Ph.D. in nucleic acid chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University.
